{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:04:43Z","timestamp":1789538683324,"version":"build-2803163510"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe abdominal Henoch-Sch\u00f6nlein purpura (HSP) can cause intense abdominal pain and gastrointestinal bleeding. Glucocorticoid therapy has limited efficacy and a high relapse rate after withdrawal. Telitacicept blocks BLyS\/APRIL and inhibits the production of pathogenic IgA immune complexes, but its use in HSP has not been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center retrospective matched cohort study. Children hospitalized with severe abdominal HSP (abdominal pain VAS \u22653, hematochezia, and extensive rash) between January 2025 and December 2025 were included. Patients were divided into a telitacicept plus glucocorticoid group (telitacicept group) and a glucocorticoid-alone group (steroid group). Individual 1:1 matching was performed based on age, sex, and disease severity. The primary outcome was time to abdominal pain relief. Secondary outcomes included time to rash resolution, disease relapse rate within 3 months after treatment, and safety. Intergroup comparisons used Wilcoxon rank-sum test or Fisher\u2019s exact test, and relapse-free time was analyzed by Kaplan\u2013Meier curves and the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 26 children (13 per group) were included. Baseline characteristics were balanced between the two groups (age, sex, age strata, all P &amp;gt; 0.05). The median time to abdominal pain relief was 3.0 days (IQR 3.0\u20134.0) in the telitacicept group, significantly shorter than the 5.0 days (IQR 4.0\u20136.0) in the steroid group (P = 0.013). Median time to rash resolution was 9.0 days in both groups, with no significant difference (P = 0.113). The 3-month relapse rate was 7.7% (1\/13) in the telitacicept group versus 46.2% (6\/13) in the steroid group; the log-rank test showed a significant difference in relapse-time distribution (P = 0.022). The number needed to treat (NNT) was 2.6. For safety, mild injection-site redness occurred in 2 patients (15.4%) in the telitacicept group, and transient hyperglycemia occurred in 1 patient (7.7%) in the steroid group. No serious adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In children with severe abdominal HSP, adding telitacicept to glucocorticoid significantly shortens the time to abdominal pain relief and reduces the short-term relapse rate, with a favorable safety profile. This study provides preliminary clinical evidence for telitacicept as an adjunctive therapy to glucocorticoids, which warrants further validation in prospective randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1865753","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:30Z","timestamp":1789536690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Addition of telitacicept to glucocorticoid reduces abdominal pain duration and relapse rate in children with severe abdominal Henoch-Sch\u00f6nlein purpura: a single-center retrospective matched cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuemei","family":"Jiang","sequence":"first","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Wang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mifeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiran","family":"Yang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Liao","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Yan","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Zhouyang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gu","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YangCui","family":"Wei","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children\u2019s Hospital","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06781-8","article-title":"A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)","volume":"42","author":"Williams","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216621","article-title":"IgA vasculitis (Henoch-Sch\u00f6nlein purpura): An update on treatment","volume":"13","author":"Casta\u00f1eda","year":"2024","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06107-7","article-title":"Early discontinuation of steroid treatment in children with abdominal pain due to IgA vasculitis","volume":"184","author":"Kambara","year":"2025","journal-title":"Eur J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020444","article-title":"Clinical use and molecular action of corticosteroids in the pediatric age","volume":"20","author":"Ferrara","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1640790","article-title":"Telitacicept as a novel B cell-targeted therapy in autoimmune encephalitis: a case report","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-026-04175-5","article-title":"Telitacicept alleviates IgA nephropathy by targeting PDHA1 lactylation to inhibit B cell metabolic reprogramming and lactate-mediated renal injury","volume":"31","author":"Xu","year":"2026","journal-title":"Eur J Med Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03777-1","article-title":"Mendelian randomization reveals association of gut microbiota with Henoch-Sch\u00f6nlein purpura and immune thrombocytopenia","volume":"120","author":"Jiang","year":"2024","journal-title":"Int J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1459394","article-title":"Gastrointestinal manifestations and pathogenesis in childhood immunoglobulin A vasculitis","volume":"12","author":"Kato","year":"2024","journal-title":"Front Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clindermatol.2016.09.013","article-title":"Acrally distributed dermatoses: Vascular dermatoses (purpura and vasculitis)","volume":"35","author":"Kazandjieva","year":"2017","journal-title":"Clinics Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2025n4b0qfm4","article-title":"Efficacy and safety of telitacicept in patients with IgAN: Results from Stage A of a Phase 3 clinical study","volume":"36","author":"Lv","year":"2025","journal-title":"J Am Soc Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:31Z","timestamp":1789536691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2026.1865753"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1865753","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1865753"}}